SHENZHEN, China–(BUSINESS WIRE)– #ChipscreenBiosciences–The Phase 1 trial will assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NW001 in patients with advanced tumors.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.